在瘤治疗中与免疫检查点抑制剂相关的B型肝炎病毒重新激活风险:一项回顾性研究

Yue Yin1, Bao Jiang Liu2, Yan Hua Zhang1

  • 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pharmacy, Peking University Cancer Hospital & Institute, Beijing 100142, China.

概括

乙型肝炎病毒 (HBV) 再激活是免疫检查点抑制剂 (ICI) 治疗癌症患者的风险. 抗病毒预防可显著降低这种风险,强调需要在ICI治疗期间对HBV监测和预防措施.